Insulin analogues are being developed to overcome the limitations of current insulin therapy by producing pharmacokinetic and pharmacodynamic profiles that more closely resemble physiological insulin release. The use of basal insulin analogues has been shown to reduce rates of hypoglycaemia, particularly at night and in individuals aiming for tight glycaemic control to minimise the risk of long-term complications. Several barriers to introducing insulin have been identified that may result in delayed achievement of glycemic control and progression of diabetes complications. These barriers include patients’ fear of injections and misconceptions about insulin therapy, clinicians’ fear of perceived complexity of insulin regimens, and both parties’ fear that introducing insulin will negatively affect patient lifestyle and weight gain. Additionally, the risk, consequences, and fear of hypoglycaemia remain a significant limiting factor in intensifying insulin therapy and optimizing glycemic control. Insulin degludec (IDeg) is an ultra-long-acting basal insulin in clinical development for the treatment of type 2 and type 1 diabetes mellitus. Soluble multi-hexamers are formed in the subcutaneous tissue upon injection, creating a depot from which monomers are slowly and continuously absorbed into the circulation. This results in a flatter and more stable pharmacokinetic and pharmacodynamic profile, with less variability in glucose-lowering activity compared with insulin glargine (IGlar). In BEGIN® phase 3a trials (total of 9 trials involving both T2DM and T1DM subjects), subjects reported fewer hypoglycaemic episodes with IDeg compared with IGlar while achieving similar glycaemic control with lower FPG level achieved in IDeg. In pre-planned meta-analysis the superiority of IDeg over IGlar was shown in rate of hypoglycaemic episodes at equivalent HbA1c using pooled, individual patient level data from all phase 3 trials of IDeg. In this talk I would like to introduce a novel ultra-long acting insulin analogue presenting advantages in flexibility of dosing time and lower risk of hypoglycemia.